Track 1: Epigenetic Disorders

Disease progression, environmental exposure, pharmacological treatment, and ageing are all caused by epigenetic alterations. Epigenetic changes can be reversed, and pharmaceutical intervention could be used to target them. Human disorders such as Fragile X syndrome, Angelman's syndrome, Prader-Willi syndrome, and certain cancers are caused by epigenetic alterations. Approximately 80% of brain illnesses are linked to several chromosomal flaws, as well as environmental variables and epigenetic processes.

Track 2: Cancer Epigenetics

Cancer Epigenetics is the study of heritable alterations in molecular mechanisms that affect the flow of information between cancer cells' DNA and their gene expression patterns. This includes comparing tumour cells to normal cells and looking at nuclear organisation, DNA methylation, Histone modification, and the effects of genetic mutations in epigenetic regulator genes. In cancer, DNA methylation patterns vary dramatically.

• Histone modification
• MicroRNA gene silencing
• Epigenetic carcinogenic
• Prostate Cancer
• Cervical cancer

Track 3: Cytogenetics

The study of chromosomal structure, chromosome location, and function in cells is known as cytogenetics. Modern cytogenetic approaches allow researchers to precisely label the chromosomal location of any gene using different coloured dots, examine cells from any type of tissue (including tumour cells), identify cells that have lost or gained a specific chromosome, and determine whether specific chromosome regions have been lost or gained without ever looking at the chromosomes under a microscope.

Track 4: Epigenetic Therapy

Drugs or epigenome-influencing techniques are used in epigenetic treatment to treat medical conditions. Histone Deactylases (HDACs), which change histones, and DNA methyltransferases (DNMTs), which methylate DNA, are two enzymes involved in epigenetic modifications and are potential targets for pharmaceutical treatment. Both enzymes have undergone successful clinical trials. Epigenetic therapy has been approved by the FDA for cutaneous T-cell lymphoma, ER-positive metastatic breast cancer, Myelodysplastic syndrome, multiple myeloma, and peripheral T-cell lymphoma, among other haematological malignancies and solid tumours. Several forms of cancer, including lung cancer, breast cancer, and lymphoma, have responded well to epigenetic therapy.

Track 5: Transgenerational Epigenetics Inheritance

Transgenerational epigenetic inheritance is the transfer of information from parents to children that changes the characteristics of future generations without altering the core structure of DNA. In organisms, the phrase "Epigenetic Inheritance" can be used to describe information transfer between cells and between species. Although these two levels of epigenetic inheritance are comparable in unicellular species, they may have different processes and evolutionary distinctions in multicellular creatures.

• Deleterious effects
• Putatively adaptive effects
• Inheritance of epigenetic marks

Track 6: Human Cognition Epigenetics

Epigenetic pathways of pathological process have been implicated in a variety of central nervous system diseases, including neurodevelopmental disorders of cognition characterised by disruptions in learning and memory. Cognition is a broad term that encompasses both the acquisition of knowledge and the ability to comprehend it. The human brain contains around 86 billion neurons, which are made up of large and small scale Synaptic Networks. These networks form structures that serve as learning and cognitive networks.

• Cognitive Neuroepigenetics
• Epigenetic code
• Role of MAPK Signaling in regulating epigenetic changes
• Epigenetic interventions

Track 7: Chromosome Biology in Agriculture

There are times when altering huge arrays of connected genes, rather than single genes, is advantageous in genetic studies or plant breeding. All of the genes on a set of chromosomes, one chromosome, or a fragment of a chromosome could be included in such arrays.

• Crop genetic engineering
• Plant artificial chromosomes
• Chromosome mechanics in plant breeding
• Chromosomal abnormalities in plants

Track 8: Genome Architecture and Functions

One of the universal features of cells, genome compaction, has emerged as a worldwide regulator of gene expression. A variety of architectural proteins, long non-coding RNAs (lncRNAs), and regulatory DNA work together to keep the cells compact.

• Chromatin print
• Genetic interaction mapping
• Functional genomics

Track 9: Immuno Genomics

Immunogenetics, sometimes known as immungenetics, is a branch of medical genetics that studies the interaction between the immune system and genetics. Autoimmune disorders, such as type 1 diabetes, are complicated hereditary features caused by immune system deficiencies. Identification of genes important for immunological defects could lead to the classification of novel target genes for treatment strategies. Genetic differences, on the other hand, can aid in defining the immunological mechanism that leads to disease.

Track 10: Chromatin and Chromosome Dynamics

A chromosome is a DNA molecule that contains all or part of the genetic material. The chromosome is formed by the condensation of chromatin. The structure of chromatin is influenced by a number of factors. The overall structure is determined by the cell cycle stage.

• Chromatin packaging
• Autosomal Chromosomes
• Sexual Chromosomes
• Chromosomal Segregation
• Centromere and Telomere
• Homo and Hetro Chromosome

Track 11: Genomes and Epigenomes

The Epigenome is the study of epigenetic alterations to a cell's genetic material. Genomics and proteomics, which are the study of a cell's genome and proteome, are related fields. By participating in critical biological systems, epigenomic maintenance (a continuous process) plays a key role in ensuring the stability of Eukaryotic genomes. Cancer-causing epigenomic markers are inhibited by plant flavones.

Track 12: Epigenetics in Pharmacology & Drug Discovery

This field is concerned with epigenetic pharmacology in order to treat epigenome disorders that are either generated during development or manifested/acquired later in life. This conference will concentrate on brain illnesses and their treatment with medications that alter the epigenome.

Track 13: Need of Epigenetic Biomarkers

The epigenome is a comprehensive account of all potentially heritable genome modifications that occur without affecting main DNA sequences. Epigenetic biomarkers are broadly characterised as quantifiable genomic alterations with preserved DNA sequence. Epigenetic regulators and manupulation are potential molecular factors that influence relevant physiological and pathological aspects, contributing to the natural history of human disease. Because these epigenetic modulators have various advantages and provide information about gene activity, they can be employed as disease biomarkers to explain discrepancies in patient endophenotypes.

Track 14: Biochemical Approaches of Epigenetics

DNA methylation, identification of methylated CpG, demethylation in mammals, histone modifications, non-coding RNAs, microRNAs, the effect of chromosome architecture, and polycomb protein mechanisms are some of the biochemical mechanisms of epigenetics. Epigenetics research using biochemical methods Methods for measuring genome-wide DNA methylation, methylation of Lysine-9 of Histone H3: involvement in heterochromatin regulation and cancer, chromatin modifications evaluating epigenetic information and distinguishing genomic characteristics and physical organisation of the nucleus.

• microRNAs
• Combined Epigenetic Therapies
• Epigenetic and Cytotoxic Therapies
• DNA methylation
• Post-translational histone modifications
• Non-coding RNA

Market Analysis

On the basis of application, the market is classified into two categories: oncology and non-oncology. Inflammatory disorders, metabolic diseases, infectious diseases, cardiovascular diseases, developmental biology, drug discovery, and other applications are classified as non-oncology, while solid tumours and liquid tumours are classified as oncology. End consumers of the market include academic and research institutes, pharmaceutical companies, biotechnology companies, and contract research organisations (CROs). Europe, North America, Asia-Pacific, and Latin America and the Caribbean are all investigated.

The global genomics market was estimated to be worth USD 15.48 billion in 2018 and is expected to grow at a CAGR of 8.6% over the forecast period. Doctors, scholars, and patients can now assess the inherited inclination to various infections thanks to the establishment of genomic information pools as a result of research activities. Clinical application of this data set is required to play a key role in modifying the human services framework for the provision of more precise, compelling, and dependable illness board arrangements. The worldwide hereditary testing market since 2015 and the market is ready to develop by USD 4.86 billion during 2020-2024 at a CAGR of over 12% during the conjecture time frame.

List of Hospitals, Research Centers and Labs

• All-Ukranian Genetics Association Experts of Medical and Laboratory Genetics
• Armenian Society of Human Genetics
• Austrian Society of Human Genetics
• Belgian Society of Human Genetics (BeSHG)
• British Society of Genetic Medicine
• Bulgarian Society of Human Genetics
• Clinical Genetics Society of Croatia
• Croatian Society of Human Genetics
• Czech Society of Medical Genetics
• Danish Society of Medical Genetics
• Dutch Society for Laboratory Specialist Clinical Genetics\
• Estonian Society of Human Genetics
• Finnish Society of Medical Genetics
• French Federation of Human Genetics
• Genetic Counselors of Belgium – GCBe
• Georgian Society of Medical Genetics and Epigenetics
• German Society of Human Genetics
• Hellenic Association of Medical Geneticists
• Hungarian Society of Human Genetics\
• Icelandic Human Genetics Society
• Irish Society of Human Genetics
• Latvian Society of Medical Genetics
• Lithuanian Society of Human Genetics
• Macedonian Society of Human Genetics
• National Board of Clinical Geneticists of Georgia